C. Ann Merrifield, Director at Lyra Therapeutics, Inc. (LYRA), bought 3,828 shares at $4.81 ($18K) on 2022-05-13, disclosed to the SEC on 2022-05-17.
Open-market purchase of $18k LYRA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.81 | 3,500 | $17K | 91.1% |
| 2 | $5.00 | 328 | $2K | 8.9% |
| Total | $4.83 avg | 3,828 | $18K | 100% |
| Filing → |
| FLXN | BUY | 2019-05-24 | $101K | — | Filing → |
| JNP | BUY | 2016-08-29 | $11K | — | Filing → |
| FLXN | BUY | 2016-06-16 | $13K | — | Filing → |